HomeMedical SpecialtiesCardiologyMinimally invasive procedure and medication benefits patients with stable coronary artery disease

Minimally invasive procedure and medication benefits patients with stable coronary artery disease

Published on

By Ana Gajic

A non-surgical procedure, called percutaneous coronary intervention (PCI), along with prescribed medication, is better than medication alone as initial treatment for people who have the most common form of heart disease, suggests an analysis of an international clinical trial co-led by St. Michael’s Hospital.

Published recently in the New England Journal of Medicine and simultaneously presented at EuroPCR 2018 in Paris, France, the five-year analysis of the FAME 2 trial shows that initial PCI along with medication was associated with a significant reduction in urgent hospital admissions and revascularizations to restore blood flow in the blood vessels of the heart and a likely reduction in heart attacks as compared to medication as the only treatment. The medication used in the FAME 2 trial consisted of a combination of aspirin, cholesterol-lowering and blood pressure-lowering drugs as required by current treatment guidelines.

PCI is a minimally-invasive procedure where modern stents – small tubular metal scaffolds coated with medication – are inserted into an artery using a small catheter to widen a narrowed blood vessel in the heart. PCI is commonly used to treat sudden blockages of a coronary artery that cause a heart attack. In situations where the heart’s arteries narrow less suddenly and do not cause a heart attack but induce chest pain during exercise – a condition known as stable coronary artery disease – it has remained unclear whether PCI in addition to medication was better than medication alone in preventing future heart attacks.

“Currently, the standard practice in North America is to prescribe medication to patients with stable coronary artery disease and avoid PCI,” said Dr. Peter Jüni, Director of the Applied Health Research Centre (AHRC) at the Li Ka Shing Knowledge Institute of St. Michael’s Hospital, who is a senior author on the study. “Our results pose the question: Would a large portion of patients benefit from early PCI in addition to medication?”

“We used pressure measurements inside the heart arteries to find coronary arteries that should be widened,” said Dr. Bernard De Bruyne, an interventional cardiologist at the Cardiovascular Center Aalst in Belgium and the Principal Investigator of the trial. “With these measurements we were able to identify patients who would benefit from PCI in addition to medication.”

The World Health Organization reports that every year, 17.7 million people die from cardiovascular diseases, which is an estimated 31 per cent of all deaths worldwide. Coronary artery disease is the most common type of heart disease in North America and Europe, and is a serious health problem worldwide. It occurs when the coronary arteries become narrow and hardened due to the build-up of cholesterol rich plaques in the blood vessels. While the FAME 2 trial showed that PCI reduced urgent hospital admissions and revascularizations and likely reduced heart attacks, it did not provide evidence for a difference between PCI and medication alone in the prevention of deaths.

The trial was initially sponsored by St. Jude Medical, a global medical device company, until the three-year follow-up. The subsequent two years of follow-up have been academically driven, organized the by the academic steering committee of the study. Nineteen sites across Europe and North America participated in the five-year follow-up.

“Our trial over its entire follow-up shows us that the longer you observe these patients, the more pronounced the benefits of the initial PCI become,” said Dr. Jüni, who is also a Canada Research Chair and a Professor of Medicine at the University of Toronto.

While Drs. Jüni and De Bruyne agree there is more research to be done using modern PCI technology, this five-year follow-up offers evidence that PCI has the potential to provide long-term benefits to patients with stable coronary artery disease.

Ana Gajic works in communications at St. Michael’s Hospital.

Latest articles

An ER doctor’s experience with long COVID – “My symptoms seemed endless”

On April 2022, another COVID wave was sweeping Toronto. It was the sixth since...

Tackling the issue of unused medication waste

When patients and programs don’t use all the medication that is prescribed, it is...

Obesity a risk factor for stillbirth, especially at term

Obesity is a risk factor for stillbirth, and the risk increases as pregnancy advances...

Prolonged cough? In most cases, patience is the treatment

Coughing after a respiratory infection is common and, in most cases, will resolve with...

More like this

Prolonged cough? In most cases, patience is the treatment

Coughing after a respiratory infection is common and, in most cases, will resolve with...

A New Era in Heart Failure Management: The Promise of Digital Therapeutics

Heart failure is one of the fastest growing cardiovascular conditions in the world that...

Funding to take LHSC developed technology global

On average it takes five to seven years to diagnose a rare disease. But,...

Milk and Colorectal Cancer: what does the research say?

Colorectal cancer is the fourth most common cancer in Canada and is more common...

Surgical guidance with AI

Researchers at UHN’s Toronto General Hospital Research Institute (TGHRI) have utilized artificial intelligence (AI)...

Report outlines public health response to COVID-19 outbreaks at mink farms

A report co-authored by Fraser Health Medical Health Officer Dr. Emily Newhouse and published...